Articles by Jim Miller - Pharmaceutical Technology

Latest Issue
PharmTech

Latest Issue
PharmTech Europe

  • Search
  • Suppliers
  • Careers

Enter a company or product name

Keyword Location
About Search
Articles by Jim Miller

Contract Services in 2012

Some recent private-equity buyouts of CROs show both the upside and downside for investors.
Feb 1, 2012

Some recent private-equity buyouts of CROs show both the upside and downside for investors.

Troublesome Signs for Bio/Pharmaceutical R&D

A dearth of late-stage candidates could hurt the pharmaceutical services market in the future
Jan 12, 2012

A dearth of late-stage candidates could hurt the pharmaceutical services market in the future.

Contract Services in 2012

Some recent private-equity buyouts of CROs show both the upside and downside for investors.
Jan 2, 2012

Some recent private-equity buyouts of CROs show both the upside and downside for investors.

Troublesome Signs for Bio/Pharmaceutical R&D

A dearth of late-stage candidates could hurt the pharmaceutical services market in the future.
Dec 2, 2011

A dearth of late-stage candidates could hurt the pharmaceutical services market in the future.

Preparing for the Last War

CROs that have made big acquisitions could be outmaneuvered by evolving sourcing models.
Nov 9, 2011

CROs that have made big acquisitions could be outmaneuvered by evolving sourcing models.

The EU Debt Crisis and CMOs

The EU debt crisis portends of possible negative repercussions for the dose CMO industry.
Oct 5, 2011

The EU debt crisis portends of possible negative repercussions for the dose CMO industry.

Preparing for the Last War

CROs that have made big acquisitions could be outmaneuvered by evolving sourcing models.
Oct 2, 2011

CROs that have made big acquisitions could be outmaneuvered by evolving sourcing models.

The EU Debt Crisis and CMOs

The EU debt crisis portends of possible negative repercussions for the dose CMO industry.
Sep 2, 2011

The EU debt crisis portends of possible negative repercussions for the dose CMO industry.

Healthy Outlook for Pharma Services

Respondents to the 2011 PharmSource-Pharmaceutical Technology Outsourcing Survey paint a positive picture, but concerns linger under the surface. This article is part of a special issue on Outsourcing.
Aug 1, 2011

Respondents to the 2011 PharmSource-Pharmaceutical Technology Outsourcing Survey paint a positive picture, but concerns linger under the surface. This article is part of a special issue on Outsourcing.

ADVERTISEMENT

LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
|Monthly
| Weekly

Survey
FDASIA was signed into law two years ago. Where has the most progress been made in implementation?
Reducing drug shortages
Breakthrough designations
Protecting the supply chain
Expedited reviews of drug submissions
More stakeholder involvement
Reducing drug shortages
70%
Breakthrough designations
4%
Protecting the supply chain
17%
Expedited reviews of drug submissions
2%
More stakeholder involvement
7%
View Results
Eric Langerr Outsourcing Outlook Eric LangerRelationship-building at Top of Mind for Clients
Cynthia Challener, PhD Ingredients Insider Cynthia ChallenerRisk Reduction Top Driver for Biopharmaceutical Raw Material Development
Jill Wechsler Regulatory Watch Jill Wechsler Changes and Challenges for Generic Drugs
Faiz Kermaini Industry Insider Faiz KermainiNo Signs of a Slowdown in Mergers
FindPharma Custom Search
Click here